Virology Journal

Table 4 Secondary outcomes in a study of the effect magnesium on patients with COVID-19

From: A randomized clinical trial investigating the impact of magnesium supplementation on clinical and biochemical measures in COVID-19 patients

Variable	Magnesium group		Placebo group
Variable	Value	P¹	Value	P¹	P²	P³
SaO2
Baseline	93.13 ± 2.36	< 0.001	94.03 ± 2.26	0.013	0.14
End of the study	97.68 ± 1.13	< 0.001	95.83 ± 1.36	0.013	0.011
Changes	4.55 ± 2.35		1.8 ± 1.67		< 0.001	0.023
Respiratory Rate
Baseline	21.10 ± 1.81	0.25	19.90 ± 2.00	0.71	0.19
End of the study	20.26 ± 1.21	0.25	19.72 ± 1.38	0.71	0.12
Changes	-0.83 ± 1.31		-0.17 ± 1.55		0.16	0.19
Fever
Baseline	36.60 ± 0.38	0.23	36.76 ± 0.37	0.37	0.35
End of the study	36.23 ± 0.25	0.23	36.39 ± 0.3	0.37	0.54
Changes	-0.37 ± 0.29		-0.37 ± 0.25		0.47	0.52
hs-CRP
Baseline	16.44 ± 3.07	0.009	17.43 ± 2.25	0.017	0.16
End of the study	14.21 ± 4.31	0.009	15.68 ± 3.72	0.017	0.17
Changes	-2.23 ± 4.31		-1.75 ± 3.72		0.65	0.53
TNF-α
Baseline	1.47 ± 4.47	0.16	1.06 ± 1.36	0.283	0.63
End of the study	0.59 ± 0.47	0.16	0.72 ± 1.16	0.283	0.55
Changes	-0.88 ± 1.51		-0.33 ± 1.24		0.54	0.105

P¹, Paired sample t-test; P², Independent sample t-test, P³, ANCOVA adjusted for weight, energy intake and serum magnesium levels at baseline; hs-CRP, High-sensitivity C-reactive protein; TNF-a, Tumor necrosis factor; SaO2, oxygen saturation of arterial blood

Back to article page

ISSN: 1743-422X

Contact us

Submission enquiries: journalsubmissions@springernature.com